claim: phylogenetic modeling explains differential sars cov-2 kinetics in lung and nasal passages in remdesivir treated rhesus macaques
evidence_1: ]: dot [@]: at [mhra]: medicines and healthcare products regulatory agency [jcvi]: joint committee for vaccination and immunisation [pmc]: penske media corporation [ covid-19]: coronavirus disease 2019 [covid-19]: coronavirus disease 2019 [v]: view this template [t]: telephone [e]: email []: you need to accept this checkbox.", "one sentence summary we developed a mathematical model to explain why remdesivir has a greater antiviral effect on sars cov-2 in lung versus nasal passages in rhesus macaques.", 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  "in rhesus macaques, early initiation of remdesivir therapy prevented pneumonia and lowered viral loads in the lung, but viral loads increased in the nasal passages five days after therapy.")